Navigation Links
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
Date:5/8/2008

REF="http://www.entremed.com" target="_new">http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate Communications & Investor Relations

EntreMed, Inc.

240.864.2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Researchers from the Southern University of ... back pain, and the acne causing P.acnes bacteria. Researchers believe ... bacteria seek out oxygen deprived location to seek shelter and ... P.acnes has the ability to live in the open joint ... spokesman for “ The best acne treatment ” explains why ...
(Date:5/20/2013)... WILMINGTON, Del. (PRWEB) May 20, 2013 ... named 14 young faculty members to its 2013 ... three years, the company will provide this outstanding ... their work in advancing basic science to meet ... is designed to help promising young and untenured ...
(Date:5/20/2013)... 2013 On 25-28 July, 2013, UPCP ... Paris - the beautiful city of lights. , According ... is revolutionizing the medical world. Understanding and integrating genetic ... hallmark of this transformation. Much of the present medical ... epidemiologic studies of large cohorts that do not take ...
(Date:5/20/2013)... Kitware, a leader in data visualization, today ... exploration of hospital costs across the United States ... recent release of “Medicare Provider Charge Data,” a dataset ... from the Centers for Medicare & Medicaid Services. , ... hospitals across the country has sparked considerable controversy; however, ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2Kitware Enables Interactive Exploration of CMS Medicare Data 2
... Corporation (NASDAQ: LIFE ) today announced it ... Conference on Tuesday, September 20 at 8:00am ET.  Greg ... present on behalf of the company. The company will ... weeks following the conference on the Life Technologies, investor ...
... Aug. 29, 2011 Chemical Abstracts Service ( CAS ... that Syngene International , an internationally reputed contract ... biotechnology company, has signed a three-year contract to provide ... award-winning chemistry research tool. SciFinder offers ...
... 26, 2011 Quantum Learning, Inc. (QLI), ... programs, and Jay Elliot, author of the book " ... announced today a licensing agreement.  Under the terms of ... training program called "Market-Leading Innovation™ (The path to Innovation ...
Cached Biology Technology:Life Technologies to Present at the UBS 2011 Global Life Sciences Conference 2Syngene Expands Ongoing Relationship with CAS to Provide SciFinder® to All Its Scientists 2Syngene Expands Ongoing Relationship with CAS to Provide SciFinder® to All Its Scientists 3Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way" 2Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way" 3
(Date:5/17/2013)... Rutgers, The State University of New Jersey, and City ... formulation called Visikol TM that effectively clears organisms ... in place of chloral hydrate, which is one of ... is tightly regulated by the Drug Enforcement Administration (DEA) ... solutions, or clearing agents, are vital for viewing organisms ...
(Date:5/17/2013)... antelope can live at elevations of 4,000-5,000m on ... in Nature Communications , investigators from Qinghai ... some genetic factors may be associated with the ... in this work will also provide implications for ... other ruminant species. , The Tibetan antelope ( ...
(Date:5/17/2013)... The Federation of American Societies for Experimental Biology ... Institutes of Health (NIH) funding trends highlighting the devastating ... critical research. The FASEB analysis follows a May 15th ... MD, PhD, who testified that the $1.6 billion cut ... is "having a substantial impact on the scientific community." ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... YORK (Dec. 19, 2007) -- Two deadly and highly infectious ... their match in a new drug developed by scientists at ... and Nipah viruses are related, newly recognized zoonotic viruses that ... larger animals -- including pigs, horses and humans. ...
... kiss you, I,ve got a cold,. But a report just published ... on an infection by shaking someone,s hand than in sharing a ... and the UK have published the first detailed report on hand ... healthcare settings. Their findings are published in the American Journal of ...
... is the first poll to reflect the discovery reported ... used to create stem cells or their near equivalents. ... than six in 10, or 63 percent, say that ... needed, 22 percent say this development means embryonic stem ...
Cached Biology News:Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports 2Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports 3If you don't want to fall ill this Christmas, then share a festive kiss but don't shake hands 2If you don't want to fall ill this Christmas, then share a festive kiss but don't shake hands 3Widespread support for nonembryonic stem cell research, VCU Life Sciences Survey shows 2
...
... is a direct antibiotic-based selection system for ... colony survival, eliminating the need for costly ... provides close to 100% accuracy in recombinant ... for robot colony picking. This cloning ...
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
... antibody raised against a partial ... Immunogen: SLC22A3 (NP_068812, 90 ... recombinant protein with GST tag. ... NM_021977 ...
Biology Products: